Graceway Takes Over Worldwide Rights To GS 9191

Graceway Pharmaceuticals (Graceway) has acquired the worldwide license, including related regulatory filings and intellectual properties from Gilead Sciences, to its’s investigational molecule, GS 9191, for topical use.

GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

A topical version of GS 9191 was evaluated for the treatment of external genital warts in a recently completed Phase 2 study. GS 9191 was well tolerated and superior to placebo in this proof of concept study.

The results sugested that GS 9191 could be a potential treatment for skin conditions characterised by excessive cellular proliferation.

Jefferson Gregory, chairman and CEO of Graceway, said: “The transaction with Gilead today is similar to our previous transaction with Pfizer in that we have licensed important compounds, processes, and intellectual properties that we hope will lead to exciting products for the treatment of important dermatological conditions faced by patients.”